Modality
Fusion Protein
MOA
CAR-T BCMA
Target
CD47
Pathway
STING
Rett
Development Pipeline
Preclinical
~Oct 2017
→ ~Jan 2019
Phase 1
~Apr 2019
→ ~Jul 2020
Phase 2
Oct 2020
→ Sep 2028
Phase 2Current
NCT08972850
1,896 pts·Rett
2020-10→2028-09·Completed
1,896 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-09-012.4y awayPh2 Data· Rett
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2
Complet…
Catalysts
Ph2 Data
2028-09-01 · 2.4y away
Rett
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08972850 | Phase 2 | Rett | Completed | 1896 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| BMR-1165 | BioMarin | Phase 2 | CD47 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Cevifotisoran | Neurocrine | Approved | CD47 |